2024년 37억 달러로 평가된 세계의 소외열대질환 치료 시장은 CAGR 4.6%를 나타내 2034년에는 58억 달러에 이를 것으로 추정됩니다. 세계보건기구에 의해 식별된 20개의 전염성 질환으로, 주로 열대·아열대 지역에 사는 사람들이 이환하고, 필요한 헬스케어에의 접근이 제한되고 있습니다.
수년간의 진전에도 불구하고 NTDs는 여전히 세계에서 10억 명 이상의 사람들에게 영향을 미치고 있으며, 기후 변화, 급속한 도시화, 사람의 이동 증가에 따라 그 만연은 더욱 가속화되고 있습니다. 시장 역학은 또한 진단학의 진보, 연구 투자의 확대, 열대 감염증에 있어서의 항균제 내성에 대한 대처의 필요성으로부터도 영향을 받고 있습니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 37억 달러 |
| 예측 금액 | 58억 달러 |
| CAGR | 4.6% |
2024년에는 뎅기열 분야에서만 세계 시장 점유율의 15%를 차지했습니다. 지난 50년 동안 보고된 사례의 수가 급격히 증가하면서 효과적인 치료 및 예방 전략의 필요성이 강조되고 있습니다.
NTDs의 치료 옵션은 약제와 백신으로 크게 나뉩니다. 2024년에는 약제 분야에서 27억 달러의 매출이 있었습니다.
미국의 소외열대질환 치료 시장은 2024년에 13억 3,000만 달러로 평가되었고, 특정 지역에 있어서의 NTD의 유병률 증가와, 정부 기관이나 자선 단체에 의한 적극적인 지원이 그 원동력이 되고 있습니다.
시장 주요 기업은 바이엘, 아스테라스 제약, 에자이 등이 있어 NTDs의 치료제이나 백신 개발의 혁신을 선도하고 있습니다.
The Global Neglected Tropical Disease Treatment Market was valued at USD 3.7 billion in 2024 and is estimated to grow at a CAGR of 4.6% to reach USD 5.8 billion by 2034. This growth reflects the increasing global focus on combating neglected tropical diseases (NTDs), which remain a persistent health challenge across low-income and developing regions. NTDs refer to a group of 20 communicable diseases identified by the World Health Organization that mainly affect individuals in tropical and subtropical regions with limited access to essential healthcare. These diseases continue to place an immense burden on underserved communities, often leading to significant morbidity, long-term disability, and mortality.
Despite years of progress, NTDs still impact more than a billion people worldwide, with climate change, rapid urbanization, and increased human mobility further accelerating their spread. Health organizations, governments, and pharmaceutical companies are stepping up collaborative efforts through mass drug administration programs, awareness campaigns, and public-private partnerships to improve access to effective treatment options. Market dynamics are further influenced by advancements in diagnostics, growing investments in research, and the need to address antimicrobial resistance in tropical infections. The demand for reliable therapeutic interventions has never been more urgent as healthcare systems around the globe push for sustainable and inclusive solutions to curb the rising incidence of these debilitating diseases.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $3.7 Billion |
| Forecast Value | $5.8 Billion |
| CAGR | 4.6% |
The Neglected Tropical Disease Treatment Market is segmented by disease type, with dengue, rabies, and trachoma among the top contributors. In 2024, the dengue segment alone accounted for 15% of the global market share. Dengue continues to emerge as a major health concern, affecting hundreds of millions every year and resulting in tens of thousands of deaths. The number of reported cases has seen a dramatic rise over the last five decades, reinforcing the critical need for effective treatments and prevention strategies. The market also addresses other high-burden conditions such as Buruli ulcer, yaws, and Chagas disease, each presenting unique treatment challenges and adding to the global healthcare load.
Treatment options for NTDs are broadly classified into drugs and vaccines. In 2024, the drug segment generated USD 2.7 billion in revenue. Anti-parasitic, antifungal, and antibiotic medications continue to be frontline tools in managing these diseases, playing a pivotal role in public health strategies to reduce infection rates and improve outcomes in vulnerable populations.
The U.S. Neglected Tropical Disease Treatment Market reached USD 1.33 billion in 2024, driven by increasing NTD prevalence in select regions and active support from government and philanthropic institutions. Organizations like the NIH are joining forces with global health bodies to expand treatment access and drive innovation.
Key players in the global market include Bayer, Astellas Pharma, and Eisai, which are leading innovations in drug and vaccine development for NTDs. These companies are prioritizing R&D, forming alliances with health organizations and governments, and aiming to deliver affordable, scalable solutions for affected communities.